O Sartor
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
Tombal B, Padhani A, Olmos D, Oh W, Nilsson S, Mastris K, Logothetis C, Lecouvet F, James N, Hussain M, Parker C, Rubin M, Tannock I, Sweeney C, Suzuki H, Sternberg C, Small E, Shore N, Sella A, Scher H, Schalken J, Heidenreich A, Gleave M, Smith M, Sartor O, Nelson P, Halabi S, Fizazi K, Efstathiou E, de Bono J, Attard G, Omlin A, Soule H, Akaza H, Fanti S, Eeles R, Drake C, De Santis M, Davis I, Daugaard G, Chinnaiyan A, Beltran H, Beer T, Gillessen Sommer S. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol 2019; 30:e3.
Dec 1, 2019Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
Dec 1, 2019Ann Oncol 2019; 30:e3
Tombal B, Padhani A R, Olmos D, Oh W K, Nilsson S, Mastris K, Logothetis C J, Lecouvet F E, James N D, Hussain M, Parker C, Rubin M A, Tannock I F, Sweeney C J, Suzuki H, Sternberg C N, Small E J, Shore N D, Sella A, Scher H I, Schalken J A, Heidenreich A, Gleave M E, Smith M R, Sartor O, Nelson P S, Halabi S, Fizazi K, Efstathiou E, de Bono J S, Attard G, Omlin Aurelius, Soule H R, Akaza H, Fanti S, Eeles R A, Drake C G, De Santis M, Davis I D, Daugaard G, Chinnaiyan A M, Beltran H, Beer T M, Gillessen Sommer Silke
Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancer
Pezaro C, James N, Logothetis C, Morgans A, Parker C, Ryan C, Saad F, Sartor O, Small E, Sternberg C, Sweeney C, Tannock I, Tombal B, Hussain M, Higano C, Omlin A, Mastris K, Attard G, Beer T, Chi K, Chowdhury S, Davis I, Drake C, de Bono J, Efstathiou E, Gravis G, Gillessen Sommer S. Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancer. Ann Oncol 2017; 28:1692-1694.
Aug 1, 2017Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancer
Aug 1, 2017Ann Oncol 2017; 28:1692-1694
Pezaro C J, James N, Logothetis C J, Morgans A, Parker C, Ryan C J, Saad F, Sartor O, Small E J, Sternberg C N, Sweeney C J, Tannock I, Tombal B, Hussain M, Higano C S, Omlin Aurelius, Mastris K, Attard G, Beer T M, Chi K N, Chowdhury S, Davis I D, Drake C G, de Bono J S, Efstathiou E, Gravis G, Gillessen Sommer Silke
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
Tombal B, Padhani A, Olmos D, Oh W, Nilsson S, Mastris K, Logothetis C, Lecouvet F, James N, Hussain M, Parker C, Rubin M, Tannock I, Sweeney C, Suzuki H, Sternberg C, Small E, Shore N, Sella A, Scher H, Schalken J, Heidenreich A, Gleave M, Smith M, Sartor O, Nelson P, Halabi S, Fizazi K, Efstathiou E, de Bono J, Attard G, Omlin A, Soule H, Akaza H, Fanti S, Eeles R, Drake C, De Santis M, Davis I, Daugaard G, Chinnaiyan A, Beltran H, Beer T, Gillessen Sommer S. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol 2016
May 2, 2016Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
May 2, 2016Ann Oncol 2016
Tombal B, Padhani A R, Olmos D, Oh W K, Nilsson S, Mastris K, Logothetis C J, Lecouvet F E, James N D, Hussain M, Parker C, Rubin M A, Tannock I F, Sweeney C J, Suzuki H, Sternberg C N, Small E J, Shore N D, Sella A, Scher H I, Schalken J A, Heidenreich A, Gleave M E, Smith M R, Sartor O, Nelson P S, Halabi S, Fizazi K, Efstathiou E, de Bono J S, Attard G, Omlin Aurelius, Soule H R, Akaza H, Fanti S, Eeles R A, Drake C G, De Santis M, Davis I D, Daugaard G, Chinnaiyan A M, Beltran H, Beer T M, Gillessen Sommer Silke
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
Tombal B, Padhani A, Olmos D, Oh W, Nilsson S, Mastris K, Logothetis C, Lecouvet F, James N, Hussain M, Parker C, Rubin M, Tannock I, Sweeney C, Suzuki H, Sternberg C, Small E, Shore N, Sella A, Scher H, Schalken J, Heidenreich A, Gleave M, Smith M, Sartor O, Nelson P, Halabi S, Fizazi K, Efstathiou E, de Bono J, Attard G, Omlin A, Soule H, Akaza H, Fanti S, Eeles R, Drake C, De Santis M, Davis I, Daugaard G, Chinnaiyan A, Beltran H, Beer T, Gillessen Sommer S. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol 2015; 26:1589-604.
Jun 3, 2015Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
Jun 3, 2015Ann Oncol 2015; 26:1589-604
Tombal B, Padhani A R, Olmos D, Oh W K, Nilsson S, Mastris K, Logothetis C J, Lecouvet F E, James N D, Hussain M, Parker C, Rubin M A, Tannock I F, Sweeney C J, Suzuki H, Sternberg C N, Small E J, Shore N D, Sella A, Scher H I, Schalken J A, Heidenreich A, Gleave M E, Smith M R, Sartor O, Nelson P S, Halabi S, Fizazi K, Efstathiou E, de Bono J S, Attard G, Omlin Aurelius, Soule H R, Akaza H, Fanti S, Eeles R A, Drake C G, De Santis M, Davis I D, Daugaard G, Chinnaiyan A M, Beltran H, Beer T M, Gillessen Sommer Silke
Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use
Lorente D, Sartor O, Su Z, Shen L, Bahl A, Ferraldeschi R, Bianchini D, Zafeiriou Z, Templeton A, Mateo J, de Bono J. Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use. Ann Oncol 2014
Dec 23, 2014Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use
Dec 23, 2014Ann Oncol 2014
Lorente D, Sartor O, Su Z, Shen L, Bahl A, Ferraldeschi R, Bianchini D, Zafeiriou Z, Templeton Arnoud, Mateo J, de Bono J S